Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy

References

• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets. 2015;19(2):201–211. doi:10.1517/14728222.2014.980235.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–2471.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. doi:10.1016/S1470-2045(16)30167-X.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Schlegel P. Emerging role of immunotherapy for childhood cancers. Chin Clin Oncol. 2018;7(2):1–18.
   PubMed Web of Science ®Google Scholar
• Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint proteins in pediatric brain and extracranial solid tumors: opportunities for immunotherapy. Clin Cancer Res. 2017;23(2):342–350. doi:10.1158/1078-0432.CCR-16-1829.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Gray J. Tumor-targeted and immune-targeted monoclonal antibodies: going from passive to active immunotherapy. Pediatr Blood Cancer. 2015;62(8):1317–1325. doi:10.1002/pbc.25508.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364–1370. doi:10.1158/1078-0432.CCR-15-0491.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Simon JS, Grosso JF, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123(19):3807–3815. doi:10.1002/cncr.30724.
   PubMed Web of Science ®Google Scholar
• Pinto N, Park JR, Murphy E, et al. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. Pediatr Blood Cancer. 2017; doi:10.1002/pbc.26613. Epub 2017 May 10.
   Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma. Paper presented at ASCO annual meeting (Abstract #10525), June 2, 2018; Chicago, USA. doi:10.1200/JCO.2018.36.15_suppl.10525.
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Wölfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54(4):400–406. doi:10.1007/s00262-004-0603-z.
   PubMed Web of Science ®Google Scholar
• Pasero C, Speiser DE, Derré L, Olive D. The Herpes virus entry mediator network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol. 2012;12(4):478–485. doi:10.1016/j.coph.2012.03.001.
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19(4):345–354. doi:10.1093/intimm/dxm014.
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Gowda M, Graham L, et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med. 2009;7(1):89. doi:10.1186/1479-5876-7-89.
   PubMedGoogle Scholar
• van Dam LS, de Zwart VM, Meyer-Wentrup FA. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Pediatr Blood Cancer. 2015;62(2):190–197.
   PubMed Web of Science ®Google Scholar
• Koirala P, Roth ME, Gill J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6:30093.
   PubMed Web of Science ®Google Scholar
• Aoki T, Hino M, Koh K, et al. Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer. 2016;63(8):1461–1464.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2(7):690–698.
   PubMed Web of Science ®Google Scholar
• Spurny C, Kailayangiri S, Jamitzky S, et al. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Pediatr Blood Cancer. 2018; doi:10.1002/pbc.26719. Epub 2017 Sep 4.
   PubMed Web of Science ®Google Scholar
• Routh JC, Ashley RA, Sebo TJ, et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol. 2008;179(5):1954–1959.
   PubMed Web of Science ®Google Scholar
• Routh JC, Grundy PE, Anderson JR, Retik AB, Kurek KC. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor. J Urol. 2013;189(4):1487–1492.
   PubMed Web of Science ®Google Scholar
• Dondero A, Pastorino F, Della Chiesa M, et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology. 2016;5(1):e1064578. doi:10.1080/2162402X.2015.1064578.
   PubMed Web of Science ®Google Scholar
• Boes M, Meyer-Wentrup F. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett. 2015;361(1):49–56. doi:10.1016/j.canlet.2015.02.027.
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000;164(8):4105–4110.
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000;6(3):283–289. doi:10.1038/73136.
   PubMed Web of Science ®Google Scholar
• Cai G, Freeman GJ. The CD160, B- and T-lymphocyte attenuator, LIGHT/ Herpes virus entry mediator pathway: a bidirectional switch regulating T-cell activation. Immunol Rev. 2009;229(1):244–258.
   PubMed Web of Science ®Google Scholar
• Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008;9(2):176–185. doi:10.1038/ni1554.
   PubMed Web of Science ®Google Scholar
• Zhang T, Ye L, Han L, He Q, Zhu J. Knockdown of Herpes virus entry mediator, a lymphocyte regulator gene, in ovarian cancer cells increases sensitivity to activated T cells. Oncol Res. 2016;24(3):189–196. doi:10.3727/096504016X14641336229602.
   PubMed Web of Science ®Google Scholar
• Lan X, Li S, Gao H, et al. Increased B- and T-lymphocyte attenuator and Herpes virus entry mediator in gastric cancer are associated with progression and poor prognosis. Onco Targets Ther. 2017;10:919–926.
   PubMedGoogle Scholar